Proprietary iPSC engineering technology designed to enable allogeneic cell products to evade host immune recognition and rejection, enabling repeat dosing and persistence without chronic immunosuppression. Applicable to NK cell, T cell, and beta islet programs for autoimmune diseases and cancer.

Allo-Evasion 5.0

Immune evasion engineering technology applied to iPSC-derived cell therapies; used in CNTY-813 islet cell replacement program for type 1 diabetes to reduce or eliminate need for chronic immunosuppression following transplantation

Biotech Distilled coverage (1)

2026-03-31 Century Therapeutics (IPSC) - Scientific Deep Dive for Allo-Evasion™ and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.